TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30415593

Group type: EXPERIMENTAL
Intervention: Ocrelizumab 600 mg every 24 weeks for ⩾120 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ocrelizumab 600 mg
Number of subjects: 0
Study: 27835715

Group type: EXPERIMENTAL
Intervention: Adjunctive ziprasidone (escitalopram + ziprasidone, n = 71)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo (escitalopram + placebo, n = 68)
Number of subjects: 139
Study: 25727243

Group type: EXPERIMENTAL
Intervention: Forward leaning body posture with inhalation of 200 μgr salbutamol
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard body posture with inhalation of 200 μgr salbutamol
Number of subjects: 41
Study: 23293168

Group type: EXPERIMENTAL
Intervention: CAS + CABG
Number of subjects: 174

Group type: COMPARATOR
Intervention: Isolated CABG
Number of subjects: 174
Study: 21183586

Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 9

Group type: COMPARATOR
Intervention: Meat diet
Number of subjects: 9
Study: 18235100

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 2707

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 2707
Study: 16996006

Group type: EXPERIMENTAL
Intervention: Neuronavigator-guided PRTTG
Number of subjects: 54

Group type: COMPARATOR
Intervention: PRTTG without neuronavigation (Control)
Number of subjects: 54
Study: 14617545

Group type: EXPERIMENTAL
Intervention: Right ventricular pacing (RVP) patients with drug resistant heart failure (group B)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Interventricular electromechanical delay or intra‐LV electromechanical delay > 50 ms in RVP patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ECG criteria for ventricular mechanical asynchrony identification in group B
Number of subjects: 16
Study: 10845431

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily for 7 days)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg twice daily for 10 days)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 493

Group type: COMPARATOR
Intervention: Cefuroxime axetil
Number of subjects: 493
Study: 9157756

Group type: EXPERIMENTAL
Intervention: Tizanidine (12 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (12 mg/day)
Number of subjects: 19
Study: 8228368

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) (160/800 mg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 3942335

Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms X kg‐1 po in addition to standard premedication 90 min before estimated induction time
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard premedication
Number of subjects: 24
Study: 30753384

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (NTZ) 600 mg twice daily for age ≥12 years; 200 mg for age 4-11 years; 100 mg for age 1-3 years for 5 days
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (NTZ)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 30558159

Group type: EXPERIMENTAL
Intervention: WB+BM- (Wheat Bran without Barley)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: WB-BM+ (Barley without Wheat Bran)
Number of subjects: 60

Group type: COMPARATOR
Intervention: WB-BM- (Control group with neither Wheat Bran nor Barley)
Number of subjects: 60
Study: 27477534

Group type: EXPERIMENTAL
Intervention: 1 per cent clotrimazole solution
Number of subjects: 120

Group type: COMPARATOR
Intervention: 3 per cent boric acid in 70 per cent alcohol
Number of subjects: 120
Study: 23726985

Group type: EXPERIMENTAL
Intervention: Immediate reporting
Number of subjects: 598

Group type: COMPARATOR
Intervention: Delayed reporting
Number of subjects: 598
Study: 22915174

Group type: EXPERIMENTAL
Intervention: 2-km treadmill walking test (76 ± 8 % VO(2max))
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Exhaustive treadmill testing
Number of subjects: 19

Group type: COMPARATOR
Intervention: Resting control condition
Number of subjects: 19
Study: 20505433

Group type: EXPERIMENTAL
Intervention: Participants recruited by NIA-funded AD research centers
Number of subjects: 769

Group type: COMPARATOR
Intervention: Participants recruited by commercial clinical sites
Number of subjects: 769

Group type: COMPARATOR
Intervention: Participants with less than college education
Number of subjects: 769

Group type: COMPARATOR
Intervention: Participants with Hamilton Depression score of 6 or more
Number of subjects: 769

Group type: COMPARATOR
Intervention: Unmarried males
Number of subjects: 769

Group type: COMPARATOR
Intervention: Nonwhites
Number of subjects: 769
Study: 18412024

Group type: EXPERIMENTAL
Intervention: Test formulation (Loprax) 400 mg cefixime
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation 400 mg cefixime
Number of subjects: 24
Study: 16361658

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 135

Group type: COMPARATOR
Intervention: Laser iridotomy
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Duration of symptoms
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Time taken to resolution of APAC
Number of subjects: 135
Study: 14512004

Group type: EXPERIMENTAL
Intervention: Acute Normovolaemic Haemodilution (ANH)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (standard fluid management)
Number of subjects: 34
Study: 11236168

Group type: EXPERIMENTAL
Intervention: TEE-guided cardioversion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Earlier cardioversion using TEE-guided approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticoagulation during and after restoration of sinus rhythm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk stratification using TEE
Number of subjects: 0
Study: 8624641

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg weekly
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg weekly, increased to 25 mg for poor responders
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 1428643

Group type: EXPERIMENTAL
Intervention: Various antenatal care practices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Practices not evaluated or shown to be ineffective
Number of subjects: 0
Study: 2869996

Group type: EXPERIMENTAL
Intervention: Intensive insulin regimen designed to maintain near‐normal glycemic levels
Number of subjects: 278

Group type: COMPARATOR
Intervention: Standard treatment with up to two insulin injections daily
Number of subjects: 278
Study: 31475795

Group type: EXPERIMENTAL
Intervention: Complete revascularization with PCI of angiographically significant nonculprit lesions
Number of subjects: 4041

Group type: COMPARATOR
Intervention: Culprit-lesion-only PCI
Number of subjects: 4041
Study: 30180960

Group type: EXPERIMENTAL
Intervention: Combination simvastatin (40 mg)/ezetimibe (10 mg)
Number of subjects: 14192

Group type: COMPARATOR
Intervention: Simvastatin (40 mg) alone
Number of subjects: 14192

Group type: EXPERIMENTAL
Intervention: No HF
Number of subjects: 14192

Group type: EXPERIMENTAL
Intervention: Pre‐existing HF
Number of subjects: 14192

Group type: EXPERIMENTAL
Intervention: De novo HF
Number of subjects: 14192
Study: 27206235

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 50
Study: 24021896

Group type: EXPERIMENTAL
Intervention: Bromfenac ophthalmic solution 0.07%
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 440
Study: 21466102

Group type: EXPERIMENTAL
Intervention: Situational salience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual cues present
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distinctiveness (architectural landmarks)
Number of subjects: 0
Study: 16060219

Group type: EXPERIMENTAL
Intervention: NaFeEDTA-fortified soy sauce (29.6 mg Fe/100 ml)
Number of subjects: 14000

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 14000
Study: 12398960

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day plus atorvastatin 10 mg/day
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day plus atorvastatin 20 mg/day
Number of subjects: 332

Group type: COMPARATOR
Intervention: Rosiglitazone plus placebo
Number of subjects: 332
Study: 9611469

Group type: EXPERIMENTAL
Intervention: Saucer-shaped Class II resin composite restorations
Number of subjects: 51

Group type: COMPARATOR
Intervention: Caries and technical deficiencies
Number of subjects: 51
Study: 7989408

Group type: EXPERIMENTAL
Intervention: Gentamicin treatment
Number of subjects: 26
Study: 2538499

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium, 4 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 4616804

Group type: EXPERIMENTAL
Intervention: Oxolinic acid (750 mg twice-daily for 14 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ampicillin (500 mg 3-times daily for 14 days)
Number of subjects: 60
Study: 12611485

Group type: EXPERIMENTAL
Intervention: G-CSF 5 microg/kg per day
Number of subjects: 61

Group type: COMPARATOR
Intervention: GM-CSF 5 microg/kg per day
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 61

Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 61
Study: 30814485

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation at home
Number of subjects: 0
Study: 30326972

Group type: EXPERIMENTAL
Intervention: Low frequency ultrasonic debridement
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-surgical sharps debridement
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 10
Study: 27237754

Group type: EXPERIMENTAL
Intervention: Severe relapse(s)
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Relapses leading to hospitalization
Number of subjects: 959
Study: 25408387

Group type: EXPERIMENTAL
Intervention: Combined use of BMI and AEC in lumbar spiral CT scans
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Subgroup 5 of group B
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Subgroup 4 and subgroup 5 parameters
Number of subjects: 100
Study: 22217457

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 1622

Group type: EXPERIMENTAL
Intervention: Fibrinolysis
Number of subjects: 1622

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1622
Study: 20124118

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129

Group type: COMPARATOR
Intervention: Problem Solving Therapy
Number of subjects: 129
Study: 17630481

Group type: EXPERIMENTAL
Intervention: rFVIIa (40, 80, or 160 microg/kg)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study: 15848703

Group type: EXPERIMENTAL
Intervention: ATG-Fresenius (4-6 mg/kg body weight)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Thymoglobulin (1.5-2.5 mg/kg body weight)
Number of subjects: 105
Study: 11932960

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole with 400 mg of didanosine (encapsulated, enteric-coated bead formulation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg fluconazole with 400 mg of didanosine (encapsulated, enteric-coated bead formulation)
Number of subjects: 0
Study: 9798189

Group type: EXPERIMENTAL
Intervention: Diclofenac-gentamicin eye drops
Number of subjects: 196

Group type: COMPARATOR
Intervention: Gentamicin eye drops
Number of subjects: 196
Study: 7665655

Group type: EXPERIMENTAL
Intervention: PCR detection of Haemophilus influenzae in nasopharyngeal secretions
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: PCR detection of Haemophilus influenzae in middle ear effusions (MEEs)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: PCR detection of P6 gene DNA in MEEs
Number of subjects: 213
Study: 2545979

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (CAV)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy using three different drug combinations
Number of subjects: 112
Study: 795456

Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal) 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal) 40 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal) 80 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal)
Number of subjects: 12
Study: 30724059

Group type: EXPERIMENTAL
Intervention: Combined sea salt-based oral rinse with Xylitol and lysozyme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tooth brushing and flossing alone
Number of subjects: 0
Study: 28476814

Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg i.v. on day 1) plus gemcitabine (1,200 mg/m2 i.v. on days 1‐8)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg i.v.) and cisplatin (60 mg/m2 i.v.) plus gemcitabine (1,000 mg/m2 i.v. on days 1‐8)
Number of subjects: 43
Study: 25912693

Group type: EXPERIMENTAL
Intervention: Renal artery denervation (RDN)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (standard pharmacotherapy)
Number of subjects: 41
Study: 23949480

Group type: EXPERIMENTAL
Intervention: LESS TEP
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional laparoscopic TEP
Number of subjects: 100
Study: 21756210

Group type: EXPERIMENTAL
Intervention: Oral lorazepam 2 mg (LOR)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 19364310

Group type: EXPERIMENTAL
Intervention: 5 mg/d of oral folic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16362296

Group type: EXPERIMENTAL
Intervention: Paclitaxel alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Paclitaxel with 1,200 mg clindamycin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Clindamycin coadministration
Number of subjects: 16
Study: 15596752

Group type: EXPERIMENTAL
Intervention: VRT with attentional cueing (experimental group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard VRT (control group)
Number of subjects: 19
Study: 11158211

Group type: EXPERIMENTAL
Intervention: Intensive lowering of blood pressure (BP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid added to antihypertensive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Different diastolic BP targets in patients with mild renal insufficiency
Number of subjects: 0
Study: 9409789

Group type: COMPARATOR
Intervention: Arthroscopic lateral retinacular release (Group I)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Open lateral retinacular lengthening (Group II)
Number of subjects: 86
Study: 8426771

Group type: EXPERIMENTAL
Intervention: Erythromycin therapy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Local isoniazid therapy (50 mg intranodal instillation)
Number of subjects: 69
Study: 3305394

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg b.i.d.
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg b.i.d.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Cefaclor 250 mg t.i.d.
Number of subjects: 125
Study: 29746878

Group type: EXPERIMENTAL
Intervention: 4-min bouts of stair climbing once every 2 hours for 8 hours
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2-min bouts of stair climbing once per hour for 8 hours
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 9
Study: 27738640

Group type: EXPERIMENTAL
Intervention: 5-ALA with SFC (200 mg 5-ALA/229.42 mg SFC per day)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 24630878

Group type: EXPERIMENTAL
Intervention: Cangrelor (500 nM) with 30 mg prasugrel
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cangrelor (500 nM) with 60 mg prasugrel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prasugrel (30 mg) without cangrelor
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prasugrel (60 mg) without cangrelor
Number of subjects: 60
Study: 22281608

Group type: EXPERIMENTAL
Intervention: Recombinant DnaK (rDnaK)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live DH5α/pTDK (Sia10-DnaK)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rDnaK
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DH5α/pTDK
Number of subjects: 0
Study: 20329655

Group type: EXPERIMENTAL
Intervention: 80 mg valsartan (test product)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 80 mg valsartan (reference product)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 24
Study: 18460998

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF, 8 mg.kg body wt)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 16401310

Group type: EXPERIMENTAL
Intervention: Fenofibrate/placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cerivastatin/placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cerivastatin/fenofibrate
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo/placebo
Number of subjects: 53
Study: 12847034

Group type: EXPERIMENTAL
Intervention: Pharmacist consultation program (face-to-face medication reviews)
Number of subjects: 889

Group type: COMPARATOR
Intervention: Control group (no pharmacist consultation)
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Pharmacist consultation program
Number of subjects: 889
Study: 10478162

Group type: EXPERIMENTAL
Intervention: Confidential prescribing feedback and targeted educational bulletins mailed every 2 months for 6 months.
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (no intervention until after completion of the study).
Number of subjects: 251
Study: 8949324

Group type: EXPERIMENTAL
Intervention: B-score system
Number of subjects: 206

Group type: COMPARATOR
Intervention: Unaided general practitioners
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: B-score prediction
Number of subjects: 206
Study: 1820589

Group type: EXPERIMENTAL
Intervention: Cinitapride
Number of subjects: 103

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 6460947

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30840197

Group type: EXPERIMENTAL
Intervention: 5000 U/m2 E. coli-derived asparaginase (ASP) IM
Number of subjects: 688

Group type: COMPARATOR
Intervention: 10000 U/m2 E. coli-derived asparaginase (ASP) IM
Number of subjects: 688
Study: 28648540

Group type: EXPERIMENTAL
Intervention: Pedicled vein harvesting
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional vein harvesting
Number of subjects: 100
Study: 25511781

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 15
Study: 25055152

Group type: EXPERIMENTAL
Intervention: Diquafosol 3% and preservative-free sodium hyaluronate 0.1% eye drops
Number of subjects: 150

Group type: COMPARATOR
Intervention: Diquafosol 3%
Number of subjects: 150

Group type: COMPARATOR
Intervention: Preserved sodium hyaluronate 0.1%
Number of subjects: 150
Study: 22998915

Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound
Number of subjects: 311

Group type: COMPARATOR
Intervention: Dutasteride pretreatment
Number of subjects: 311
Study: 19239354

Group type: EXPERIMENTAL
Intervention: Immediate switch in therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Delayed switch (when plasma HIV-1 RNA became > or =10,000 copies/ml)
Number of subjects: 47
Study: 17690017

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) targeting pain catastrophizing
Number of subjects: 34

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 34
Study: 15142271

Group type: EXPERIMENTAL
Intervention: Industry-sponsored drug trials
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Design bias in RCTs
Number of subjects: 45
Study: 11579889

Group type: EXPERIMENTAL
Intervention: Artesunate and PSD
Number of subjects: 287

Group type: COMPARATOR
Intervention: Control (untreated mothers)
Number of subjects: 287
Study: 9662762

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 500 mg twice daily for 3 days
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Erythromycin, 500 mg four times daily for 7 days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cotrimoxazole (trimethoprim 160 mg + sulfamethoxazole 800 mg), twice daily for 7 days
Number of subjects: 46
Study: 8161719

Group type: EXPERIMENTAL
Intervention: Oral solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tablets (reference)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intramuscular injection
Number of subjects: 12
Study: 3278496

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.65 MAC)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Halothane (0.65 MAC)
Number of subjects: 13
Study: 2030299

Group type: EXPERIMENTAL
Intervention: Low energy laser treatment (Mid 1500 Irradia laser, wavelength 904 nm, average power output 12 mW, peak value 8.3 W, frequency 70 Hz, pulse train 8000 Hz) applied locally to 6 sites for 30 sec each, total of 10 treatments over 2-3 weeks.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo treatment (details not provided)
Number of subjects: 49
Study: 1250945

Group type: EXPERIMENTAL
Intervention: Etifoxine 300 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: d‐amphetamine 5 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31658145

Group type: EXPERIMENTAL
Intervention: Intracoronary tirofiban
Number of subjects: 100
Study: 30914350

Group type: EXPERIMENTAL
Intervention: Aqueous extract of saffron capsule (200 mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Routine stroke care (control group)
Number of subjects: 39
Study: 28073615

Group type: EXPERIMENTAL
Intervention: QPL-Only
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: QPL-plus-Coach
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 114
Study: 25548846

Group type: EXPERIMENTAL
Intervention: 10 units of HBTX‐A
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: 20 units of HBTX‐A
Number of subjects: 488

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 488